Suning Chen

3.9k total citations
231 papers, 1.7k citations indexed

About

Suning Chen is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Suning Chen has authored 231 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Hematology, 72 papers in Molecular Biology and 72 papers in Genetics. Recurrent topics in Suning Chen's work include Acute Myeloid Leukemia Research (113 papers), Chronic Myeloid Leukemia Treatments (55 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (35 papers). Suning Chen is often cited by papers focused on Acute Myeloid Leukemia Research (113 papers), Chronic Myeloid Leukemia Treatments (55 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (35 papers). Suning Chen collaborates with scholars based in China, United States and Taiwan. Suning Chen's co-authors include Depei Wu, Depei Wu, Aining Sun, Yang Xu, Huiying Qiu, Xiaowen Tang, Qinrong Wang, Jian Zhang, Xiaofeng Lai and Jinlan Pan and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Suning Chen

209 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suning Chen China 19 771 712 333 273 209 231 1.7k
Jiong Hu China 21 661 0.9× 976 1.4× 412 1.2× 106 0.4× 217 1.0× 105 1.8k
Siyi Zhang China 15 565 0.7× 713 1.0× 229 0.7× 244 0.9× 70 0.3× 56 1.6k
Shingo Yano Japan 23 956 1.2× 478 0.7× 506 1.5× 349 1.3× 309 1.5× 173 1.9k
Roberto Passetto Falcão Brazil 26 584 0.8× 958 1.3× 371 1.1× 357 1.3× 306 1.5× 132 2.2k
Charlotte van Kesteren Netherlands 22 747 1.0× 256 0.4× 375 1.1× 88 0.3× 191 0.9× 45 1.6k
Baoan Chen China 21 480 0.6× 514 0.7× 239 0.7× 195 0.7× 77 0.4× 90 1.2k
Güray Saydam Türkiye 22 678 0.9× 533 0.7× 278 0.8× 515 1.9× 59 0.3× 160 1.6k
Yuping Gong China 20 268 0.3× 669 0.9× 231 0.7× 138 0.5× 108 0.5× 83 1.2k
Jumei Shi China 21 728 0.9× 1.0k 1.5× 535 1.6× 124 0.5× 48 0.2× 90 2.0k
Eberhard Schleyer Germany 24 1.1k 1.5× 438 0.6× 461 1.4× 563 2.1× 353 1.7× 69 1.8k

Countries citing papers authored by Suning Chen

Since Specialization
Citations

This map shows the geographic impact of Suning Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suning Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suning Chen more than expected).

Fields of papers citing papers by Suning Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suning Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suning Chen. The network helps show where Suning Chen may publish in the future.

Co-authorship network of co-authors of Suning Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Suning Chen. A scholar is included among the top collaborators of Suning Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suning Chen. Suning Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yujie, Jiaqi Li, Ying Wang, et al.. (2025). Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients. Hematological Oncology. 43(3). e70081–e70081. 2 indexed citations
2.
Fan, Yuanyuan, Xiqin Zhang, Jianqi Zhao, Suning Chen, & Jingjing Liang. (2024). Cancer cell membrane-camouflaged curcumin nanoparticles trigger ferroptosis for accurate gastric cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics. 204. 114509–114509. 13 indexed citations
3.
4.
Wang, Huafeng, Xudong Wei, Qian Jiang, et al.. (2024). Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6541–6541. 1 indexed citations
5.
Liu, Ziyi, et al.. (2024). Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia. British Journal of Haematology. 204(4). 1219–1226. 1 indexed citations
6.
7.
Dong, Ningzheng, et al.. (2024). The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study. Leukemia & lymphoma. 65(13). 1964–1973. 1 indexed citations
8.
Lin, Dandan, Ying Shen, Hong Liu, et al.. (2023). Critical role of MXRA7 in differentiation blockade in human acute promyelocytic leukemia cells. Experimental Hematology. 125-126. 45–54. 2 indexed citations
9.
Zhang, Zhiyu, Yingxin Sun, & Suning Chen. (2023). Case Report: Off-label treatment of idiopathic hypereosinophilic syndrome with Omalizumab. Frontiers in Pharmacology. 14. 1095737–1095737. 1 indexed citations
10.
Wang, Man, et al.. (2023). Case report: Identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement. Frontiers in Oncology. 12. 1028651–1028651. 8 indexed citations
11.
Wang, Qian, Hongjie Shen, Zixuan Ding, et al.. (2023). Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib. SHILAP Revista de lepidopterología. 11(1). e6801–e6801. 2 indexed citations
12.
Wang, Wenjuan, et al.. (2022). Identification of variants in 94 Chinese patients with hereditary spherocytosis by next‐generation sequencing. Clinical Genetics. 103(1). 67–78. 6 indexed citations
13.
Huo, Li, Wenzhi Cai, Qinrong Wang, et al.. (2022). Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations. Hematology. 27(1). 1184–1190. 5 indexed citations
14.
Xiang, Xin, et al.. (2022). Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics. Hematology. 27(1). 499–505. 2 indexed citations
15.
Qi, Jiaqian, Yuanxin Zhu, Yang Xu, et al.. (2021). Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemia. Hematological Oncology. 39(3). 358–363. 2 indexed citations
16.
Wen, Lijun, et al.. (2021). Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 22(6). 393–404. 3 indexed citations
17.
Zhang, Jian, Xinyou Zhang, Lili Zhou, et al.. (2020). Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 56(5). 1056–1064. 21 indexed citations
18.
Cen, Jiannong, et al.. (2017). Myeloid neoplasms with t(12;22)(p13;q12)/MN1-EVT6: a systematic review of 12 cases. Annals of Hematology. 97(3). 417–424. 8 indexed citations
19.
Hu, Zhilin, Bin Song, Lei Xu, et al.. (2016). Aqueous synthesized quantum dots interfere with the NF-κB pathway and confer anti-tumor, anti-viral and anti-inflammatory effects. Biomaterials. 108. 187–196. 39 indexed citations
20.
Tao, Huiquan, et al.. (2014). Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia. Leukemia & lymphoma. 56(2). 472–479. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiong Hu Breakdown of academic impact, for papers by Siyi Zhang Breakdown of academic impact, for papers by Shingo Yano Breakdown of academic impact, for papers by Roberto Passetto Falcão Breakdown of academic impact, for papers by Charlotte van Kesteren Breakdown of academic impact, for papers by Baoan Chen Breakdown of academic impact, for papers by Güray Saydam Breakdown of academic impact, for papers by Yuping Gong Breakdown of academic impact, for papers by Jumei Shi Breakdown of academic impact, for papers by Eberhard Schleyer
Rankless by CCL
2026